PROSTATEnow Testing Overview
Test name: PROSTATEnow™ for Hereditary Prostate Cancer Risk
Purpose of test: There is an increased likelihood of a genetic mutation in patients with certain personal and family history characteristics and various clinical criteria. The PROSTATEnow™ test makes a diagnosis of HBOC pathogenic variant to increase preventative treatment options. This expanded panel includes additional genes that are associated with hereditary prostate.
Genes tested:
ATM, BRCA1, BRCA2, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, NBN, PMS2, PALB2, RAD51D, TP53
Disorders Associated: Prostate cancer. Additional cancers include breast, ovarian, fallopian tube and peritoneal cancers, prostate cancer and pancreatic cancer
Ordering Requirements:
Specimen Source:
Peripheral (whole) blood collected 4ml blood in a purple top EDTA tube
Analytical Validity: The analytical sensitivity is >99.97% of described gross deletion and duplication mutations
Purpose of test: There is an increased likelihood of a genetic mutation in patients with certain personal and family history characteristics and various clinical criteria. The PROSTATEnow™ test makes a diagnosis of HBOC pathogenic variant to increase preventative treatment options. This expanded panel includes additional genes that are associated with hereditary prostate.
Genes tested:
ATM, BRCA1, BRCA2, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, NBN, PMS2, PALB2, RAD51D, TP53
Disorders Associated: Prostate cancer. Additional cancers include breast, ovarian, fallopian tube and peritoneal cancers, prostate cancer and pancreatic cancer
Ordering Requirements:
- Informed Consent
- Genetic Counseling Pre-test
- Genetic Counseling Post-Test
- Other required documents
Specimen Source:
Peripheral (whole) blood collected 4ml blood in a purple top EDTA tube
Analytical Validity: The analytical sensitivity is >99.97% of described gross deletion and duplication mutations
